ADJUVANT CHEMORADIOTHERAPY IN GASTRIC CANCER
Session type: Poster / e-Poster / Silent Theatre session
Theme: Diagnosis and therapy
Adjuvant chemoradiotherapy (CRT) has become a therapeutic option since the publication of the Results of Mac- Donald study test showing a significant improvement in overall survival. We report the Results of postoperative CRT after curative resection in gastric cancer patients
This is a retrospective study including 38 patients with gastric cancer treated in our department of radiotherapy oncology of Blida with adjuvant CRT, during a period of 10 years (from January 2001 to December 2011). CRT was indicated for patients with insufficient lymph node dissection and/or lymph node involvement and/or positive surgical margins. The chemotherapy consisted of 5-FU alone, FUFOL, LV5FU2 or LV5FU2 Cisplatin regimen, associated with 45 to 60 Gy of radiotherapy (depending on the surgical margin).
The median age was 48,6 years with a sex ratio of 1,6. Twenty seven patients had total gastrectomy. Lymph node dissection was insufficient for 14 patients and lymph node involvement was seen in 37 patients. Surgical margins were positive for 8 patients. The median time between surgery and CRT was 2,2 months. FUFOL regimen and 5FU alone were the most used protocols (32% and 40%, respectively).The recurrence rate after CRT was 51% with a median survival of 35 months. The survival rates at 2, 3 and 5 years were 52%, 47% and 23%, respectively. Grade 3-4 hematologic and gastrointestinal toxicities were noted in 15% and 20% of patients respectively. The factors significantly affecting survival were the patients general condition at diagnosis, the seat of the primary tumor and positive surgical margins
Our Results in terms of median survival and 3 year overall survival were comparable to those in the literature especially with Mac Donald study. As for prognostic factors, our Results confirm the findings of several studies published in the literature